Top

Published in:

01-07-2009 | Original Article

Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma

Authors: Kyung Hwa Lee, Sang Woo Lim, Ho Gun Kim, Dong Yi Kim, Seong Yeob Ryu, Jae Kyun Joo, Jung Chul Kim, Jae Hyuk Lee

Published in: Langenbeck's Archives of Surgery | Issue 4/2009

Abstract

Background and aims

To determine the underlying mechanism for the differential expression, the extent of promoter methylation in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-related genes acting downstream of TRAIL was examined in early and advanced gastric carcinomas.

Methods

The extent of promoter methylation in the DR4, DR5, DcR1, DcR2, and CASP8 genes was quantified using bisulfite modification and methylation-specific polymerase chain reaction.

Results

The promoters for DcR1, DcR2, and CASP8 were largely unmethylated in early gastric carcinoma, advanced gastric carcinoma, and controls, with no significant difference among them. Protein levels of DR4, DcR1, and DcR2 as revealed by immunohistochemistry correlated with the extent of the respective promoter methylation (P < 0.05 in all cases). Hypomethylation, rather than hypermethylation, of the DR4 promoter was noted in invasive gastric malignancies, with statistical significance (P = 0.003).

Conclusion

The promoter methylation status of TRAIL receptors in gastric carcinoma may have clinical implications for improving therapeutic strategies in patients with gastric carcinoma.

Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462. doi:10.1126/science.7878464 PubMedCrossRef

Nagata (1997) Apoptosis by death factor. Cell 88:355–365PubMedCrossRef

Pitti RM, Marsters SA, Ruppert S et al (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–12690. doi:10.1074/jbc.271.22.12687 PubMedCrossRef

MacFarlane M, Ahmad M, Srinivasula SM et al (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272:25417–25420. doi:10.1074/jbc.272.41.25417 PubMedCrossRef

Pan G, Ni J, Wei YF et al (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815–818. doi:10.1126/science.277.5327.815 PubMedCrossRef

Kischkel FC, Lawrence DA, Chuntharapai A et al (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611–620. doi:10.1016/S1074-7613(00)80212-5 PubMedCrossRef

Marsters SA, Sheridan JP, Pitti RM et al (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003–1006. doi:10.1016/S0960-9822(06)00422-2 PubMedCrossRef

Jo M, Kim TH, Seol DW et al (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564–567. doi:10.1038/75045 PubMedCrossRef

Thorburn A, Behbakht K, Ford H (2008) TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 11:17–24. doi:10.1016/j.drup.2008.02.001 PubMedCrossRef

10.

Herman JG, Baylin SB (2000) Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 249:35–54PubMed

11.

Fulda S, Kufer MU, Meyer E et al (2001) Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20:5865–5877. doi:10.1038/sj.onc.1204750 PubMedCrossRef

12.

Fenoglio-Preiser C, Munoz N, Carneiro F et al (2000) Gastric Carcinoma. In: Hamilton SR, Aaltonen LA (eds) Pathology and genetics of tumors of the digestive system (WHO classification of tumours). Lyon, IARC, pp 39–52

13.

Greene FL, Page DL, Fleming ID (2002) AJCC cancer staging manual, 6th ed, vol 2. New York, Springer, pp 99–106CrossRef

14.

Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S et al (1999) Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting. J Pathol 189:344–350PubMedCrossRef

15.

Herman JG, Graff JR, Myohanen S et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826. doi:10.1073/pnas.93.18.9821 PubMedCrossRef

16.

Shi SR, Cote RJ, Yang C et al (1996) Development of an optimal protocol for antigen retrieval: a 'test battery' approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol 179:347–352. doi:10.1002/(SICI) 1096-9896(199607)179:3<347::AID-PATH559>3.0.CO;2-L PubMedCrossRef

17.

Freitas S, Moore DH, Michael H et al (2003) Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 9:4689–4694PubMed

18.

Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162. doi:10.1172/JCI6926 PubMedCrossRef

19.

Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821. doi:10.1126/science.277.5327.818 PubMedCrossRef

20.

van Geelen CM, de Vries EG, de Jong S (2004) Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7:345–358. doi:10.1016/j.drup.2004.11.002 PubMedCrossRef

21.

Koornstra JJ, Kleibeuker JH, van Geelen CM et al (2003) Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200:327–335. doi:10.1002/path.1364 PubMedCrossRef

22.

Kuraoka K, Matsumura S, Sanada Y et al (2005) A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep 14:465–470PubMed

23.

Ledig S, Wagner S, Manns MP et al (2004) Role of the receptor-mediated apoptosis in Helicobacter pylori in gastric epithelial cells. Digestion 70:178–186. doi:10.1159/000082252 PubMedCrossRef

24.

Takahashi M, Yasui H, Ogura AO et al (2008) X irradiation combined with TNF alpha-related apoptosis-inducing ligand (TRAIL) reduces hypoxic regions of human gastric adenocarcinoma xenografts in SCID mice. J Radiat Res (Tokyo) 49:153–161CrossRef

25.

Eggert A, Grotzer MA, Zuzak TJ et al (2000) Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 35:603–607. doi:10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1 PubMedCrossRef

26.

Shivapurkar N, Toyooka S, Eby MT et al (2002) Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1:65–69PubMed

27.

Hopkins-Donaldson S, Ziegler A, Kurtz S et al (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10:356–364. doi:10.1038/sj.cdd.4401157 PubMedCrossRef

28.

Kanehara I, Nakata B, Hirakawa K (2005) Caspase-8 is scarcely silenced and its activity is well correlated with the anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand in gastric cancer cells. Oncol Rep 14:1249–1253PubMed

29.

Soung YH, Lee JW, Kim SY et al (2005) CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 65:815–821PubMed

30.

Koyama S (2003) Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis. J Gastroenterol Hepatol 18:763–770. doi:10.1046/j.1440-1746.2003.03055.x PubMedCrossRef

31.

Shimoyama S, Mochizuki Y, Kusada O et al (2002) Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 21:643–648PubMed

32.

Park WS, Lee JH, Shin MS et al (2001) Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121:1219–1225. doi:10.1053/gast.2001.28663 PubMedCrossRef

Title: Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma
Authors: Kyung Hwa Lee
Sang Woo Lim
Ho Gun Kim
Dong Yi Kim
Seong Yeob Ryu
Jae Kyun Joo
Jung Chul Kim
Jae Hyuk Lee
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 4/2009
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-009-0484-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma

Abstract

Background and aims

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2009

A case with synchronous multiple liver metastases from gastric carcinoma: postoperative long-term disease-free survival

Hepatic infestation of Echinococcus multilocularis with extension to regional lymph nodes

Extended liver resection after preoperative chemotherapy: influence on regeneration and endoplasmic reticulum stress response

Pleural and pericardial morbidity after minimal access repair of pectus excavatum

Unusual case of massive hemorrhage of a gastric duplication cyst in a very advanced age

Does tumor size have an impact on gastric cancer? A single institute experience